PD28-01 DOES PRE-OPERATIVE MULTI-DRUG RESISTANT URINE CULTURE PREDICT INFECTIOUS COMPLICATIONS AFTER PERCUTANEOUS NEPHROLITHOTOMY?
| Autor: | William Shi, Roger L. Sur, Charles Lakin, Michelle Ritter, David Wenzler, Nishant Patel, Michael A. Liss, Omer A. Raheem, Craig S Schallhorn |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
medicine.medical_specialty
business.industry Urology medicine.medical_treatment Cancer Urine urologic and male genital diseases medicine.disease Pre operative chemistry.chemical_compound chemistry Docetaxel Cabazitaxel medicine Enzalutamide Multi drug resistant business Percutaneous nephrolithotomy medicine.drug |
| Zdroj: | Journal of Urology. 191 |
| ISSN: | 1527-3792 0022-5347 |
| DOI: | 10.1016/j.juro.2014.02.2112 |
| Popis: | RESULTS: Maximun median PSA response was -22% (-76% e 76%). Forty-six percent of patients had a >30% decrease in PSA. The PSA response to enzalutamide did not correlate to the number of prior cancer treatments (p 1⁄4 0.57), time from diagnosis to CRPC (p 1⁄4 0.11), or prior response to docetaxel (p 1⁄4 0.67). However, 8 patients treated with 2nd line Cabazitaxel had an inferior PSA response to enzalutamide (p1⁄4 0.03), and there was a trend for the PSA response to abiraterone to correlate with the PSA response to the succeeding enzalutamide (B1⁄40.22, p 1⁄4 0.05). The maximum median alkaline phosphatase response was 0.1% (-67% e 126%). Median OS was 4.8 months. CONCLUSIONS: Patients with post-chemo, post-Abiraterone mCRPC can obtain a PSA response with enzalutamide therapy. However, the biochemical response to therapy compared seems lower than reported in the AFFIRM study. Whether this is an effect of crossresistance or a result of the natural history of the disease needs further elaboration. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|